Advertisement
|
|
|
|
|
Free Trial
Description: John Musser is Pharmagenesis COO. With a Lead411 subscription, Pharmagenesis email addresses ( @pharmagenesis.net ) of the executives are viewable. Other information includes John Musser email, phone, and extension.
Be sure to check our Linkedin tab on the company page. Typical management titles include VP, Chief, Vice President, Director, manager, & more. Similar names to Musser can be found at Executive Directory - Musser.
|
Add John Musser Information
Site Reference: http://www.pharmagenesis.net/Management.htm
John H. Musser, Ph.D., Chief Operating Officer
Before
joining Pharmagenesis, Inc. in 1995, Dr. Musser was Vice President of Chemistry and a
Corporate Officer at Glycomed. There he built
and led Chemical R&D with a focus on carbohydrates.
Product candidates included ilomastat, a matrix metalloproteinase inhibitor to
treat ocular ulceration which reached Phase III clinical trials, astenose, a heparin
derivative to treat restenosis following balloon angioplasty with an IND filed in 1994,
and celadin, a pre-IND sialyl Lewis X analog to treat sepsis. An IPO was filed in 1991 employing Montgomery
Securities. Corporate collaborations included
Eli Lilly, Genentech and Sankyo. Glycomed
merged with Ligand Pharmaceutical in 1995. From
1982 to 1991, Dr. Musser was at Wyeth first as Manager than as Director of Medicinal
Chemistry. His department initiated the
rapamycin immune suppression chemical research program.
Rapamycin (sirolimus, RapamuneŽ
|
|
| Copyright 2010 Lead411 | Santa Barbara, CA |
|
|
|
|
Advertisement
|
